Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2025-12-26 @ 4:09 AM
Study NCT ID:
NCT00939627
Status:
COMPLETED
Last Update Posted:
2018-01-23
First Post:
2009-07-14
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-07
Start Date Type:
None
Primary Completion Date:
2013-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-01
Completion Date Type:
ACTUAL
First Submit Date:
2009-07-14
First Submit QC Date:
None
Study First Post Date:
2009-07-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-07-28
Results First Submit QC Date:
None
Results First Post Date:
2015-09-01
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-12-28
Last Update Post Date:
2018-01-23
Last Update Post Date Type:
ACTUAL